Evidence network for deaths_(OS)

1SYSUCC-002, 20221SOLAR-1 (patients with PIK3CA mutant status), 20191CALGB 40302, 20141EGF30008 (HER2-positive), 20091PALOMA-3, 20161PENELOPE-B, 20211KCSG-BR15-10, 20191MONALEESA-2, 20161MONARCH 2, 20202E2112, 2021 ENCORE301, 20131PALOMA-1, 20161MONALEESA-3, 20182BELLE-2 (full population), 2017 BELLE-2 (patients with known PI3K status), 20171NCT02756364 (sapanisertib weekly), 20221NCT02187991 - HR-positive and HER2-negative cohort, 20211QUILT-2.015, 20131Huang, 2020aromatase inhibitorfulvestrantletrozoleendocrine therapyexemestanepaclitaxelexemestane plus ridaforolimuschemotherapytrastuzumab plus endocrine therapycapecitabineplacebotrastuzumab plus chemotherapyabemaciclib plus aromatase inhibitoralpelisib plus fulvestrantlapatinib plus fulvestrantlapatinib plus letrozolepalbociclib plus fulvestrantpalbociclib plus endocrine therapyribociclib plus letrozoleribociclib plus endocrine therapyabemaciclib plus fulvestrantabemaciclib plus endocrine therapyentinostat plus exemestanepalbociclib plus letrozoleribociclib plus fulvestrantipatasertib plus paclitaxelbuparlisib plus fulvestranttaselisib plus letrozolesapanisertib plus fulvestrantdalpiciclib plus fulvestranttucidinostat plus exemestanealisertib plus paclitaxelcapivasertib plus paclitaxeldalotuzumab plus ridaforolimus plus exemestanealpelisib plus letrozoleganitumab plus endocrine therapyOBI-822/OBI-821 plus cyclophosphamidetrastuzumab emtasine plus endocrine therapytrastuzumab emtansinemetformincelecoxib plus endocrine therapybuparlisib plus letrozolecediranib plus fulvestrantdirect evidencenetwork meta-analysis
T vs. C aromatase inhibitorfulvestrantletrozoleendocrine therapyexemestanepaclitaxelexemestane plus ridaforolimuschemotherapytrastuzumab plus endocrine therapycapecitabineplacebotrastuzumab plus chemotherapyabemaciclib plus aromatase inhibitoralpelisib plus fulvestrantlapatinib plus fulvestrantlapatinib plus letrozolepalbociclib plus fulvestrantpalbociclib plus endocrine therapyribociclib plus letrozoleribociclib plus endocrine therapyabemaciclib plus fulvestrantabemaciclib plus endocrine therapyentinostat plus exemestanepalbociclib plus letrozoleribociclib plus fulvestrantipatasertib plus paclitaxelbuparlisib plus fulvestranttaselisib plus letrozolesapanisertib plus fulvestrantdalpiciclib plus fulvestranttucidinostat plus exemestanealisertib plus paclitaxelcapivasertib plus paclitaxeldalotuzumab plus ridaforolimus plus exemestanealpelisib plus letrozoleganitumab plus endocrine therapyOBI-822/OBI-821 plus cyclophosphamidetrastuzumab emtasine plus endocrine therapytrastuzumab emtansinemetformincelecoxib plus endocrine therapybuparlisib plus letrozolecediranib plus fulvestrant
aromatase inhibitor---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
fulvestrantNA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
letrozoleNANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
endocrine therapyNANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
exemestaneNANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
paclitaxelNANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
exemestane plus ridaforolimusNANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
chemotherapyNANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab plus endocrine therapyNANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
capecitabineNANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
placeboNANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab plus chemotherapyNANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
abemaciclib plus aromatase inhibitorNANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
alpelisib plus fulvestrantNANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
lapatinib plus fulvestrantNANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
lapatinib plus letrozoleNANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANA
palbociclib plus fulvestrantNANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANA
palbociclib plus endocrine therapyNANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANA
ribociclib plus letrozoleNANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANA
ribociclib plus endocrine therapyNANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANA
abemaciclib plus fulvestrantNANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANA
abemaciclib plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANA
entinostat plus exemestaneNANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANA
palbociclib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANA
ribociclib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANA
ipatasertib plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANA
buparlisib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANA
taselisib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANA
sapanisertib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANA
dalpiciclib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANA
tucidinostat plus exemestaneNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANA
alisertib plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANA
capivasertib plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANA
dalotuzumab plus ridaforolimus plus exemestaneNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANA
alpelisib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANA
ganitumab plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANA
OBI-822/OBI-821 plus cyclophosphamideNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANA
trastuzumab emtasine plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANA
trastuzumab emtansineNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANA
metforminNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANA
celecoxib plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANA
buparlisib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NA
cediranib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---

pathologies: 4,319,144,356,351,357,352,354,353,358,359 - treatments: 1447 result logic